Celgene fights for sanction on patent challenger Bass

Carly Helfand

 is hedge fund manager Kyle ' latest target, it says–but the biotech isn't taking the news lying down.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS